THINWES: BRAND INSIGHTS

A monthly update to keep you Informed

TOPIC OF THE MONTH
BLEEDING OESOPHAGEAL VARICES: A MEDICAL BRIEF SNAPSHOT
Portal hypertension is
a major complication
of chronic liver disease.
In cirrhosis,
architectural distortion
of the liver causes an
increase in the
intrahepatic vascular
resistance.
Gastro-oesophageal
varices form as a result
of increased portal
pressure, the product
of increased portal
venous inflow and
resistance to outflow
from the portal venous
system
Gastro-oesophageal
varices are present in
almost half of patients
at the time of the
diagnosis of cirrhosis
The 6-week mortality
for variceal bleeding is
approximately 10%,
and the 1-year
recurrence rate of
variceal bleeding is
60%
1 4 2 3
BOV & HRS : A Major complications of Cirrhosis
CURRENT RECOMMENDED MANAGEMENT OF PATIENTS WITH ACUTE VARICEAL
BLEEDING
ROLE OF THINWES
Indications
Indications
In the management of :
Bleeding Oesophageal Varices
Hepato Renal Syndrome
Pharmacological
Benefits
significantly decreases portal venous flow
Decrease hepatic venous pressure gradient & mortality
Terlipressin & Albumin significantly decreases serum creatinine levels & improves renal
function.
Dosage
Bleeding Oesophageal Varices is 2mg IV bolus every 4-6hrs which can be continued upto a
maximum of 72 hrs.
In Hepato renal Syndrome, the dosage is 1-2mg bolus every 4-6 hrs maximun of 2mg every 4-
6 hrs.
MECHANISM OF ACTION
THINWES ADVANTAGES
Highly efficacious in BOV with better survival rates which makes Terlipressin a drug of
choice amongst clinicians
Well documented benefits in Hepato Renal Syndrome
Single shot bolus every 4-6 hours
No Tachyphylaxis or desensitization with repeated dose
Lesser hospital stay
MARKET TREND
Brand Company Sum of MAT (May 13) Sum of MAT (May 14)
TERLYZ SUN* 7.7 8.9
TERLIFORCE ALEMBIC 3.4 3.1
THINWES BIOCON 0.8 3
TERLISTAT SAMARTH PHARMA 2 1.8
T-PRESSIN UNITED BIOTECH 0 0.9
REMESTYP FERRING PHARMA 0.7 0.4
TERLIBAX RANBAXY* 0 0.1
TRIPEZ UNIQUE PHARM 0.2 0.1
TRESIL SERUM INSTITUTE 0 0
TOTAL
14.7 18.2
Total competitors: 9 Total Market Value: 18.2 Growth: 24%
COMPETITOR MARKET OVERVIEW
TERLYZ
49%
TERLIFORCE
17%
THINWES
16%
TERLISTAT
10%
T-PRESSIN
5%
REMESTYP
2%
TERLIBAX
1%
OTHER
0%
Brand Company Growth Volume led growth
(VLG)
Price led growth
(PLG)
TERLYZ SUN* 15% 12% 3%
TERLIFORCE ALEMBIC -10% -11% 1%
THINWES BIOCON 255% 255% 0%
TERLISTAT SAMARTH PHARMA -8% 14% -22%
T-PRESSIN UNITED BIOTECH - - -
REMESTYP FERRING PHARMA -32% -32% 0%
TERLIBAX RANBAXY* - - -
COMPETITOR PRICE INSIGHTS
Brand MRP
Thinwes (1 mg/10 ml) 2000/-
Terlyz (1 mg/10 ml) 1380/-
Remestyp 2000/-
BRAND SEGMENTATION AND POSITIONING
Strength Packing MRP (per vial)
Terlipressin inj.
1 mg
1mg / 10 ml
vial
2000
THINWES PACKAGING AND PRICING
Speciality Targeting Positioning
Targeted Drs/
TBM
Indication
Gastroenterol
ogists (Surg. &
Physicians)
All BOV
Ceases
Bleeding,
Restores Life
Hepatologists All BOV
Intensivists All BOV, HRS
Con.
Physicians
20 BOV, HRS
BRAND INSIGHTS